First biosimilar Herceptin approved in India amid calls for genuinely affordable pricing
This article was originally published in Scrip
Executive Summary
Biocon has received marketing authorization in India for its biosimilar version of Roche's Herceptin (trastuzumab), developed under a partnered program with Mylan.